Jae-Eun Myung, MPharm, Liesl Strachan, PhD, Jaeyong Shin, MD, PhD, Jaejun Yim, MA, Sang-Soo Lee, PhD, MBA

DHTs can create substantial value by supporting frontline healthcare providers with additional tools to diagnose or prevent disease and increase efficiencies, enabling the potential for better and more targeted clinical decision making and the ability to improve clinical outcomes. To ensure DHTs can be used effec-tively in medical practice, a more flexible and bespoke approach to reimbursement and payment determination is required. Ef-forts need to be taken to ensure the broad scope of DHTs is eligible for assessment, which can include anything from medical applications, software supporting healthcare professionals’ clin-ical decision, wearable devices, telehealth, and telemedicine. This should combine with flexible approaches to reimbursement and payment determinations, in particular the use of value frame-works that consider the characteristics, intended use, perfor-mance, safety, effectiveness, and comprehensive value for each category of DHTs.

This could be accomplished through continuous real-world evidence generation to reduce uncertainties and demonstrate clinical and economic value in the Korean population. DHTs that are deemed safe and of value could be made available earlier using value-based healthcare criteria and innovative funding mechanisms. This will benefit not only patients but healthcare providers and the health authorities that manage the NHI program.

원문 바로가기